338 related articles for article (PubMed ID: 19754386)
101. Dysregulated Leukotriene Metabolism in Patients with COVID-19.
Doğan HO; Budak M; Doğan K; Zararsız GE; Yerlitaş Sİ; Bolat S; Şenol O; Büyüktuna SA; Pınarbaşı E; Sarıismailoğlu R; Yavuz H
Jpn J Infect Dis; 2024 May; 77(3):129-136. PubMed ID: 38171849
[TBL] [Abstract][Full Text] [Related]
102. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?
Sharma JN; Mohammed LA
Inflammopharmacology; 2006 Mar; 14(1-2):10-6. PubMed ID: 16835707
[TBL] [Abstract][Full Text] [Related]
103. 5-Lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents.
Jampilek J; Dolezal M; Opletalova V; Hartl J
Curr Med Chem; 2006; 13(2):117-29. PubMed ID: 16472209
[TBL] [Abstract][Full Text] [Related]
104. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands.
Alestas T; Ganceviciene R; Fimmel S; Müller-Decker K; Zouboulis CC
J Mol Med (Berl); 2006 Jan; 84(1):75-87. PubMed ID: 16388388
[TBL] [Abstract][Full Text] [Related]
105. Leukotriene C(4) synthase.
Lam BK
Prostaglandins Leukot Essent Fatty Acids; 2003; 69(2-3):111-6. PubMed ID: 12895593
[TBL] [Abstract][Full Text] [Related]
106. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis.
Crosslin DR; Shah SH; Nelson SC; Haynes CS; Connelly JJ; Gadson S; Goldschmidt-Clermont PJ; Vance JM; Rose J; Granger CB; Seo D; Gregory SG; Kraus WE; Hauser ER
Hum Genet; 2009 Mar; 125(2):217-29. PubMed ID: 19130089
[TBL] [Abstract][Full Text] [Related]
107. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population.
Sayers I; Barton S; Rorke S; Sawyer J; Peng Q; Beghé B; Ye S; Keith T; Clough JB; Holloway JW; Sampson AP; Holgate ST
Clin Exp Allergy; 2003 Aug; 33(8):1103-10. PubMed ID: 12911785
[TBL] [Abstract][Full Text] [Related]
108. 5-Lipoxygenase-activating protein (FLAP).
Vickers PJ
J Lipid Mediat Cell Signal; 1995 Oct; 12(2-3):185-94. PubMed ID: 8777565
[No Abstract] [Full Text] [Related]
109. The potential role of antileukotriene drugs in atherosclerosis.
Spanbroek R; Habenicht AJ
Drug News Perspect; 2003 Oct; 16(8):485-9. PubMed ID: 14668944
[TBL] [Abstract][Full Text] [Related]
110. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability.
Qiu H; Gabrielsen A; Agardh HE; Wan M; Wetterholm A; Wong CH; Hedin U; Swedenborg J; Hansson GK; Samuelsson B; Paulsson-Berne G; Haeggström JZ
Proc Natl Acad Sci U S A; 2006 May; 103(21):8161-6. PubMed ID: 16698924
[TBL] [Abstract][Full Text] [Related]
111. Leukotriene synthesis is increased by transcriptional up-regulation of 5-lipoxygenase, leukotriene A4 hydrolase, and leukotriene C4 synthase in asthmatic children.
Zaitsu M; Hamasaki Y; Matsuo M; Ichimaru T; Fujita I; Ishii E
J Asthma; 2003 Apr; 40(2):147-54. PubMed ID: 12765316
[TBL] [Abstract][Full Text] [Related]
112. Pharmacogenetics of the 5-lipoxygenase pathway in asthma.
Silverman E; In KH; Yandava C; Drazen JM
Clin Exp Allergy; 1998 Nov; 28 Suppl 5():164-70; discussion 171-3. PubMed ID: 9988463
[TBL] [Abstract][Full Text] [Related]
113. [Leukotriene-lipoxygenase pathway and drug discovery].
Abe M; Yoshimoto T
Nihon Yakurigaku Zasshi; 2004 Dec; 124(6):415-25. PubMed ID: 15572846
[TBL] [Abstract][Full Text] [Related]
114. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations.
Steinbrink SD; Pergola C; Bühring U; George S; Metzner J; Fischer AS; Häfner AK; Wisniewska JM; Geisslinger G; Werz O; Steinhilber D; Maier TJ
Cell Mol Life Sci; 2010 Mar; 67(5):797-806. PubMed ID: 20091083
[TBL] [Abstract][Full Text] [Related]
115. Influence of leukotriene gene polymorphisms on chronic rhinosinusitis.
Al-Shemari H; Bossé Y; Hudson TJ; Cabaluna M; Duval M; Lemire M; Vallee-Smedja S; Frenkiel S; Desrosiers M
BMC Med Genet; 2008 Mar; 9():21. PubMed ID: 18366797
[TBL] [Abstract][Full Text] [Related]
116. Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.
Kolasa T; Bhatia P; Brooks CD; Hulkower KI; Bouska JB; Harris RR; Bell RL
Bioorg Med Chem; 1997 Mar; 5(3):507-14. PubMed ID: 9113329
[TBL] [Abstract][Full Text] [Related]
117. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
[TBL] [Abstract][Full Text] [Related]
118. cDNA cloning, expression, mutagenesis, intracellular localization, and gene chromosomal assignment of mouse 5-lipoxygenase.
Chen XS; Naumann TA; Kurre U; Jenkins NA; Copeland NG; Funk CD
J Biol Chem; 1995 Jul; 270(30):17993-9. PubMed ID: 7629107
[TBL] [Abstract][Full Text] [Related]
119. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.
Fang WF; Douglas IS; Wang CC; Kao HC; Chang YT; Tseng CC; Huang KT; Chang HC; Lin MC
PLoS One; 2014; 9(7):e102622. PubMed ID: 25025775
[TBL] [Abstract][Full Text] [Related]
120. Cysteinyl leukotrienes mediate the enhancing effects of indomethacin and aspirin on eosinophil production in murine bone marrow cultures.
Elsas PX; Queto T; Mendonça-Sales SC; Elsas MI; Kanaoka Y; Lam BK
Br J Pharmacol; 2008 Feb; 153(3):528-35. PubMed ID: 18037915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
